| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Serine/threonine-protein kinase PLK4, Polo-like kinase 4, PLK-4, Serine/threonine-protein kinase 18, Serine/threonine-protein kinase Sak, PLK4, SAK, STK18 |
| Entrez GeneID | 10733 |
| WB Predicted band size | 109.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This PLK4 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 724-758 amino acids from the region of human PLK4. |
+ +
以下是3篇关于PLK4抗体的代表性文献摘要(信息基于公开研究整理，非实时数据库检索)：
---
1. **文献名称**: *"Polo-like kinase 4 controls centriole duplication but does not directly regulate cytokinesis"*
**作者**: Habedanck R. et al.
**摘要**: 该研究利用PLK4特异性抗体验证其在中心体复制中的核心作用，发现PLK4敲除导致中心体缺失，但未直接参与细胞分裂的最终阶段。抗体染色显示PLK4定位于中心体周围基质。
2. **文献名称**: *"Structural basis of PLK4 activation through autophosphorylation and its targeting by cancer drugs"*
**作者**: Slevin L.K. et al.
**摘要**: 通过PLK4抗体进行免疫共沉淀和结构解析，揭示了PLK4自磷酸化激活机制，并发现部分临床抗癌化合物通过抑制PLK4激酶结构域发挥抗肿瘤作用。
3. **文献名称**: *"Overexpression of PLK4 correlates with poor prognosis in gastric cancer and promotes tumor cell proliferation"*
**作者**: Li J. et al.
**摘要**: 使用PLK4抗体对胃癌组织进行免疫组化分析，发现PLK4高表达与患者生存率下降显著相关，体外实验证实其通过调控细胞周期蛋白促进肿瘤生长。
---
注：如需实际引用，请通过PubMed或Web of Science核实文献准确性及最新研究进展。
PLK4 (Polo-like kinase 4) is a serine/threonine kinase belonging to the Polo-like kinase family, which plays a critical role in regulating centrosome duplication and mitotic progression. As a master regulator of centriole biogenesis, PLK4 ensures precise control of the centrosome cycle, maintaining genomic stability. Dysregulation of PLK4 expression is linked to various diseases, particularly cancers, where its overexpression has been observed in tumors such as breast, colorectal, and hepatocellular carcinomas. Conversely, PLK4 depletion can induce centrosome abnormalities, mitotic errors, and cell death, highlighting its dual role as both an oncogene and a tumor suppressor depending on cellular context.
PLK4 antibodies are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect PLK4 levels in cells or tissues. Specific monoclonal or polyclonal antibodies targeting distinct epitopes enable researchers to explore post-translational modifications, protein-protein interactions, and kinase activity. In cancer research, PLK4 antibodies help correlate PLK4 expression with tumor progression, metastasis, or therapeutic response. Recent studies also focus on developing PLK4 inhibitors as anticancer agents, making these antibodies critical for validating drug efficacy and target engagement. However, challenges remain in ensuring antibody specificity due to structural similarities within the kinase family. Overall, PLK4 antibodies are pivotal in advancing our understanding of cell division mechanisms and their implications in disease.
×
